Vancouver, Canada, and Taipei, Taiwan – SynMatrix has been selected as the official investment advisor for Asia Particle Co., Ltd.’s pioneering Boron Neutron Capture Therapy (BNCT) project. The project, which focuses on innovative cancer treatment, aims to establish a Special Purpose Vehicle (SPV) to advance BNCT technology and operations in both the United States and Taiwan.

Under this advisory agreement, SynMatrix will leverage its extensive networks to identify and connect potential investors, assist in preparing investment materials, and provide strategic insights to strengthen investor relations. The collaboration is outlined in a mutual Non-Disclosure Agreement (NDA), ensuring confidentiality and intellectual property protection throughout the engagement.

“We are honored to partner with Asia Particle Co. on this groundbreaking BNCT project, which has the potential to revolutionize cancer treatment,” said Alexis Liu, Managing Director of SynMatrix Consulting. “Our role as investment advisor reflects our commitment to supporting transformative healthcare solutions.”

This partnership highlights SynMatrix's dedication to fostering impactful international collaborations in advanced healthcare, supporting Asia Particle’s mission to bring cutting-edge BNCT treatments to market and improve patient outcomes globally.

© 2024 SynMatrix Consulting, Inc. All Rights Reserved.